Ring Therapeutics Announces Appointment of Bioprocess and Biomanufacturing Veteran Konstantin Konstantinov, Ph.D. as Chief Technology Officer
"We are delighted to welcome Konstantin as the newest addition to our growing executive leadership team,” said Tuyen Ong, MD, MBA, Chief Executive Officer of Ring Therapeutics and CEO-Partner at Flagship Pioneering.
- "We are delighted to welcome Konstantin as the newest addition to our growing executive leadership team,” said Tuyen Ong, MD, MBA, Chief Executive Officer of Ring Therapeutics and CEO-Partner at Flagship Pioneering.
- “He is a true trailblazer, and his wealth of industry knowledge and experience in the bioprocessing and biomanufacturing of numerous products will prove invaluable to Ring as we build out a pipeline of our novel AnelloVector therapeutics.
- Prior to Codiak, he was the Vice President of Late-Stage Process Development responsible for bioprocess and technology development at Genzyme/Sanofi’s Boston Hub.
- Notably, Dr. Konstantinov has published more than 60 peer reviewed papers and has over 15 patents and patent applications.